Civica has signed a seven-year agreement with Thermo Fisher Scientific to develop Civica-owned abbreviated new drug applications.
Through the partnership, Civica will begin to build its internal pipeline of medications.
At first, the Thermo Fisher collaboration will focus on nine critical medications that have been in shortage or are at risk of being in shortage because they only have one manufacturer.
Civica said owning its own drugs is a key component of its manufacturing strategy and will further mitigate the risk of drug shortages in the future.
To date, Civica has only worked with drug manufacturers that already have FDA-approved manufacturing plants and the capacity to produce Civica-labeled drugs. Those partnerships were struck to get medications in shortage to the market more quickly, the company said.
“We are thrilled to enter into a partnership with a world-class organization that is dedicated to helping Civica serve patients,” said Martin VanTrieste, Civica’s president and CEO. “The Thermo Fisher team is known for top manufacturing talent, supply reliability, product quality and innovation. We look forward to working with them to develop and produce Civica medicines.”
More articles on pharmacy:
CVS to add 600 HealthHUBs, link them to lower Aetna copays
Civica Rx calls on generic drugmakers to donate to its cause
Pfizer, GlaxoSmithKline give timeline for IPO of joint venture
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.